- Home
- KZIA vs SSKN Comparison
KZIA vs SSKN Comparison
Compare KZIA & SSKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- SSKN
- Stock Information
- Founded
- KZIA 1994
- SSKN 1989
- Country
- KZIA Australia
- SSKN United States
- Employees
- KZIA N/A
- SSKN N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- SSKN Medical/Dental Instruments
- Sector
- KZIA Health Care
- SSKN Health Care
- Exchange
- KZIA Nasdaq
- SSKN Nasdaq
- Market Cap
- KZIA 9.0M
- SSKN 8.9M
- IPO Year
- KZIA 1999
- SSKN 2005
- Fundamental
- Price
- KZIA $6.71
- SSKN $1.61
- Analyst Decision
- KZIA Strong Buy
- SSKN Strong Buy
- Analyst Count
- KZIA 3
- SSKN 1
- Target Price
- KZIA $16.00
- SSKN $6.00
- AVG Volume (30 Days)
- KZIA 188.3K
- SSKN 5.5M
- Earning Date
- KZIA 11-14-2025
- SSKN 11-12-2025
- Dividend Yield
- KZIA N/A
- SSKN N/A
- EPS Growth
- KZIA N/A
- SSKN N/A
- EPS
- KZIA N/A
- SSKN N/A
- Revenue
- KZIA $1,549,158.00
- SSKN $32,848,000.00
- Revenue This Year
- KZIA N/A
- SSKN N/A
- Revenue Next Year
- KZIA $49.25
- SSKN $9.70
- P/E Ratio
- KZIA N/A
- SSKN N/A
- Revenue Growth
- KZIA 248983.08
- SSKN 0.36
- 52 Week Low
- KZIA $2.86
- SSKN $1.38
- 52 Week High
- KZIA $39.05
- SSKN $3.86
- Technical
- Relative Strength Index (RSI)
- KZIA 41.14
- SSKN 43.31
- Support Level
- KZIA $6.82
- SSKN $1.82
- Resistance Level
- KZIA $7.39
- SSKN $2.22
- Average True Range (ATR)
- KZIA 0.45
- SSKN 0.21
- MACD
- KZIA 0.02
- SSKN -0.03
- Stochastic Oscillator
- KZIA 28.33
- SSKN 7.83
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About SSKN Strata Skin Sciences Inc.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.